

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NEPTUNE GENERICS, LLC,  
APOTEX INC., APOTEX CORP., TEVA PHARMACEUTICALS,  
FRESENIUS KABI USA, LLC, and  
WOCKHARDT BIO AG  
Petitioners,

v.

ELI LILLY & COMPANY,  
Patent Owner.

---

Case No: IPR2016-00237<sup>1</sup>  
Patent No. 7,772,209

---

**PATENT OWNER'S UPDATED EXHIBIT LIST**

---

<sup>1</sup> Cases IPR2016-01190, IPR2016-01335, and IPR2016-01341 have been joined with the instant proceeding.

EXHIBIT	DESCRIPTION
2001	Lilly Eli & Co. Form 10-k Annual Report filed February 19, 2016 for the Period Ending December 31, 2015
2002	Alimta Prescribing Information revised September 2013
2003	<i>Eli Lilly and Co. v. Teva Parenteral Medicines Inc. et al.</i> , Civil Action No. 1:10-cv-01376, Defendants' Opening Post-Trial Brief Regarding the Invalidity of U.S. Patent No. 7,772,209, dated October 11, 2013
2004	<i>Eli Lilly and Co. v. Teva Parenteral Medicines Inc. et al.</i> , Civil Action No. 1:10-cv-01376, Plaintiff Eli Lilly and Company's Post-Trial Brief, dated November 22, 2013
2005	<i>Eli Lilly and Co. v. Teva Parenteral Medicines Inc. et al.</i> , Civil Action No. 1:10-cv-01376, Defendants' Trial Brief Regarding the Invalidity of U.S. Patent No. 7,772,209, dated June 14, 2013
2006	<i>Eli Lilly and Co. v. Teva Parenteral Medicines Inc. et al.</i> , Civil Action No. 1:10-cv-01376, Joint Trial Exhibit List, dated August 18, 2013
2007	Exhibit Number Not Used
2008	<i>Eli Lilly and Co. v. Teva Parenteral Medicines et al.</i> , United States Court of Appeals for the Federal Circuit Case 15-2067, Notice of Docketing, dated September 25, 2015
2009	<i>Eli Lilly and Co. v. Teva Parenteral Medicines et al.</i> , United States Court of Appeals for the Federal Circuit Case 15-2067, Order on Motion to Modify Briefing Schedule, dated November 5, 2015
2010	United States Court of Appeals for the Federal Circuit Internal Operating Procedures
2011	Exhibit Number Not Used
2012	Trial Exhibit TX 910, Abstract 2139, American Society of Clinical Oncology Thirty Fourth Annual Meeting Program Volume 17, dated May 16-19, 1998

2013	Declaration of Bruce A. Chabner, M.D. Concerning Exhibits 2014 and 2015 [Not Filed]
2014	Abstract 2139, American Society of Clinical Oncology Thirty Fourth Annual Meeting Program Volume 17, dated May 16-19, 1998. (Stamped Univ. of Minn. Bio-Medical Library) [Not Filed]
2015	Niyikiza, <i>et al.</i> , LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, 17: 558a, Abstract 2139 (1998) (“Niyikiza II”)
2016	The New Shorter Oxford English Dictionary on Historical Principles [excerpt] Vol. 2, pg. 2123 (1993)
2017	Random House Unabridged Dictionary [excerpt], 2nd Ed., pg. 1421 (1993)
2018	Affidavit of Adam L. Perlman In Support of Motion For <i>Pro Hac Vice</i> Admission Pursuant to 37 C.F.R. § 42.10(c)
2019	Transcript of July 22, 2016 Teleconference with the Board
2020	PDR 53rd (1999)
2021	ABPI COMPENDIUM OF DATA SHEET AND SUMMARIES OF PRODUCT CHARACTERISTICS 1998-99:1542-45 (1998) (“ABPI Compendium of Data Sheets”)
2022	Rinaldi, <i>et al.</i> , A phase I evaluation of LY231514, a novel multitargeted antifolate, administered every 21 days, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, 15: 489, Abstract 1559 (1996) (“Rinaldi I”)
2023	Declaration of W. Archie Bleyer, M.D., FRCP [GLASG] (IPR2016-00237 Proceeding)

2024	Declaration of W. Archie Bleyer, M.D., FRCP [GLASG] (IPR2016-00240 Proceeding)
2025	PDR 52nd (1998)
2026	Deposition Transcript of Ron D. Schiff, M.D. (August 25, 2016) [ <b>Not Filed</b> ]
2027	Deposition Transcript of W. Archie Bleyer, M.D., FRCP [GLASG] Part 1 (August 30, 2016)
2028	Deposition Transcript of W. Archie Bleyer, M.D., FRCP [GLASG] Part 2 (August 31, 2016)
2029	Exhibit Number Not Used
2030	Rinaldi, <i>Overview of Phase I Trials of Multitargeted Antifolate (MTA, LY 231514)</i> , SEMINARS IN ONCOLOGY, 26 (2:6): 82-88 (1999) (Stamped Univ. Wisconsin Health Sciences Library) (“Rinaldi II”)
2031	Laohavinij, <i>et al.</i> , <i>A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid</i> , INVESTIGATIONAL NEW DRUGS, 14: 325-335 (1996) (“Laohavinij”)
2032	VIDAL LE DICTIONNAIRE, 21, 30 & 1985-1986 (1998) [w/ Translation] (“Vidal 1998”)
2033	Quinn <i>et al.</i> , <i>Evaluation of Homocysteine and Excitatory Amino Acid Neurotransmitters in the CSF of Children Who Received Methotrexate for the Treatment of Cancer</i> , JOURNAL OF CLINICAL ONCOLOGY, 15: 2800-2806 (1997) (“Quinn”)
2034	Calvert, <i>MTA: Summary and Conclusions</i> , SEMINARS IN ONCOLOGY, 26(2:6): 105-108 (1999) (Stamped Univ. of Wisconsin Health Sciences Library) (“Calvert II”)

2035	Hammond, <i>et al.</i> , <i>A phase I and pharmacokinetic (PK) study of the multitargeted antifol (MTA) LY231514 folic acid</i> , AMERICAN SOCIETY OF CLINICAL ONCOLOGY, 17: 225a, Abstract 866 (1998) (“Hammond II”)
2036	Exhibit Number Not Used
2037	Dierkes, <i>et al.</i> , <i>Supplementation With Vitamin B12 Decreases Homocysteine and Methylmalonic Acid But Also Serum Folate in Patients With End-Stage Renal Disease</i> , METABOLISM, 48(5): 631-635 (1999) (Stamped Univ. of Wisconsin Health Sciences Library) (“Dierkes”)
2038	Gulati, <i>et al.</i> , <i>Posttranscriptional Regulation of Mammalian Methionine Synthase by B 12</i> , BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 259: 436-442 (1999) (“Gulati”)
2039	Exhibit Number Not Used
2040	Smith, <i>et al.</i> , <i>Enhanced Antitumor Activity for the Thymidylate Synthase Inhibitor 1843U89 through Decreased Host Toxicity with Oral Folic Acid</i> , CANCER RESEARCH, 55:6117-6125 (1995) (“Smith & Amyx”)
2041	Z. P. Sofyina, <i>et al.</i> , <i>Possibility to Increase the Antitumor Effect of Folic Acid Antagonist with the Help of Methylcobalamine Analogs</i> , SCIENTIFIC CENTER ONCOLOGY, 1:72-78 (1979) (“Sofyina”) (Lilly Translation)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.